SEARCH
Enter your search term below:
Azellon Cell Therapeutics
Professor Anthony Hollander
“The University of Bristol and SETsquared were a great double-act in supporting Azellon in the company’s early days.”
Professor Anthony Hollander
In each of the knees there are two pieces of fibrous tissue called the menisci that cushion the two bone-ends.
They are commonly torn because of a sporting injury leading to pain and swelling. Surgery to remove the damaged meniscus can lead to premature osteoarthritis.
Azellon’s meniscal repair technology combines bone marrow stem cells with a special membrane that helps to deliver the cells into the injured site and initiate biological repair.
Top 3 achievements:
- Brought in investment and grant funding from IP Group, Wellcome UTA and Innovate UK to get the company off the ground.
- Pitched Azellon to Hugh Osmond (Pizza Express; Punch Taverns; Sun Capital) who decided to invest and led subsequent investment rounds.
- Concluded a first-in-human clinical trial with encouraging results.
